Phase-Appropriate Implementation of GMPs: Ensuring Quality in Drug Development
IN THE REALM OF PHARMACEUTICAL DEVELOPMENT, THE REGULATORY AUTHORITIES MANDATE THE GRADUAL INTEGRATION of Good Manufacturing Practice (GMP) quality systems as drugs progress through development. This dynamic approach protects patient safety, ensures product quality, and proactively manages risks. The overarching goal is to craft processes and products that seamlessly transition to commercial settings, ensuring a steady supply of high-quality products. Failing to apply phase-appropriate GMPs leads to significant consequences, apart from the heightened risks to product quality and patient safety. Such consequences include regulatory obstacles and an inability to control the material supply chain effectively, which can cause shortages, delays, and increased costs. From the preliminary research and development stages to the culmination of Phase 3 clinical trials, GMPs underpin the process of manufacturing drug products. These practices establish the foundation for reliability and quality, guiding drug substances towards their eventual commercialization. IN THE INITIAL STAGES OF RESEARCH AND DEVELOPMENT, while strict GMP rules may not apply, essential principles are expected to be upheld. This entails meticulous documentation, calibrated lab equipment and use of standardized methods. The integrity of data and careful labeling of research materials are of paramount importance. The foundational expectations set by general laboratory practices remain a cornerstone for maintaining accuracy and credibility. AS DRUG DEVELOPMENT PROGRESSES TO PRECLINICAL STUDIES, further implementation of GMP controls becomes expected, along with adherence to Good Laboratory Practices (GLP). During this phase, the emphasis lies on employing high-quality starting materials, adhering to good documentation practices, and implementing written methods/procedures describing test
20
Fall | Automne 2023
BIOTECanada
methodology. This collective effort ensures safety as the drug progresses toward Phase 1 clinical trials. PHASE 1 CLINICAL TRIALS require the application of applicable GMPs to ensure consistent and high-quality manufacturing. Raw materials and study materials must be labeled, segregated, and traceable at all times. Manufacturing processes, including sanitation measures, should be well-documented, consistently recorded, and controlled to ensure product uniformity. Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) are documented and tracked, serving as guiding benchmarks for scaling the process. Accurate records of manufacturing and testing data must be maintained, while qualified personnel and a Quality Assurance (QA) function play essential roles. Environmental controls and equipment maintenance ensure stringent quality standards. Material consistency with preclinical studies is essential. A comprehensive testing strategy, covering raw materials, in-process elements, packaging, and final products, is enforced. Validation of analytical methods and stability testing provide essential checkpoints. At this point while a full vendor qualification is not required, the vendor selection must take into consideration the reputation and reliability of the vendor. CONTINUING INTO PHASE 2A CLINICAL TRIALS, the focus remains on ensuring consistent manufacturing and product quality. Establishing controls for critical process parameters is crucial to maintain uniformity, while documentation integrity remains a constant priority. PHASE 2B CLINICAL TRIALS echo the principles of Phase 2a, with a heightened emphasis on scalability and process validation. This entails the implementation of fully qualified test methods and comprehensive documentation. Validation of manufacturing processes continues with preliminary in-process controls. Documentation practices are robust, including comprehensive batch records and validation reports.